Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo
The treatment of vitiligo remains disappointing especially in some localization such as bony prominences and extremities. The association of UVB and topical steroids has been proven to be synergistic but the results are still insufficient in those difficult to treat areas. Promising results have been shown with the combination of laser assisted dermabrasion, topical 5FU and UVB. The investigators hypothesize that the dermabrasion of vitiligo skin followed by topical steroids should potentialized the effect of UVB and be superior to topical steroids and UVB without dermabrasion.
The main objective of this study is to evaluate the usefulness of laser assisted dermabrasion combined to topical steroids and UVB phototherapy in difficult to treat areas.
Patients with symmetrical non segmental vitiligo will be included in this prospective randomized monocentrer study. The investigators calculated the number of patients needed at 25. The side that will receive the dermabrasion will be centrally randomized and the opposite side will serve as control. Then on both side class 3 topical steroids will be applied daily 3 weeks on 4 for 12 weeks. UVB phototherapy will be performed twice weekly also for 12 weeks.
The evaluation will be performed by two independent physician blinded to the treatment of standardized photos before and 1 month after the end of the treatment. The criteria of success will be at least 75% of repigmentation.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究場所
-
-
Alpes-Maritimes
-
Nice、Alpes-Maritimes、フランス、06001
- CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age between 18 at 85
- Not segmental Vitiligo of clinical diagnosis located on bony projections or of ends
- Two symmetrical plates of vitiligo of more than 4 cm ²
Exclusion Criteria:
- Pregnant women or breastfeeding.
- Vitiligo lesions on face and neck
- Personal history of skin cancer
- Photosensitize drugs
- Personal history of photodermatosis
- Personal history of keloids
- Concomitant treatment that could have an action on vitiligo (such as tacrolimus or pimecrolimus).
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Group Laser = Arm As A
Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
|
Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
|
|
プラセボコンパレーター：Bras B : the control group
patient to accept habitual treatment of corticoid
|
patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Lesions that will receive the treatment by dermabrasion associate to habitual treatment of topical steroids and UVB phototherapy
時間枠：4 months
|
Opposite side lesions that will received only the treatment by topical steroids and UVB phototherapy
|
4 months
|
協力者と研究者
捜査官
- 主任研究者：PASSERON Ph Thierry, Md、CHU de Nice - Service de Dermatologie - Hôpital de l'Archet - 151 Route de saint-antoine de ginestière 06200 Nice
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Group Laser = Arm Aの臨床試験
-
Centre Francois BaclesseRoche Pharma AG; Hospira, now a wholly owned subsidiary of Pfizer; Vifor Pharma終了しました
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)引きこもった
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Federico II University; Humanitas Clinical and Research Center; Istituto Oncologico Veneto IRCCS; European Institute of Oncology と他の協力者募集乳がん | トリプルネガティブ乳がん | 断食 | 食事による暴露イタリア